Globus Medical (GMED) Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMED, but not buy additional shares or sell existing shares.
View GMED analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued 12-month price objectives for Globus Medical's shares. Their GMED share price forecasts range from $61.00 to $78.00. On average, they predict the company's stock price to reach $70.50 in the next year. This suggests a possible upside of 34.3% from the stock's current price.
View analysts price targets for GMED or view top-rated stocks among Wall Street analysts.

Globus Medical's stock was trading at $74.27 on January 1st, 2023. Since then, GMED shares have decreased by 29.3% and is now trading at $52.51.
View the best growth stocks for 2023 here.

Globus Medical saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 7,700,000 shares, an increase of 24.0% from the April 30th total of 6,210,000 shares. Based on an average daily trading volume, of 1,460,000 shares, the short-interest ratio is currently 5.3 days. Currently, 10.0% of the company's shares are short sold.
View Globus Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our GMED earnings forecast.

Globus Medical, Inc. (NYSE:GMED) posted its earnings results on Thursday, May, 4th. The medical device company reported $0.53 EPS for the quarter, topping analysts' consensus estimates of $0.51 by $0.02. The medical device company had revenue of $276.90 million for the quarter, compared to the consensus estimate of $254.05 million. Globus Medical had a net margin of 18.82% and a trailing twelve-month return on equity of 12.26%. The company's revenue for the quarter was up 20.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.42 EPS.

ETFs with the largest weight of Globus Medical (NYSE:GMED) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Indxx Medical Devices ETF (MDEV), SPDR S&P Health Care Equipment ETF (XHE), First Trust Innovation Leaders ETF (ILDR), First Trust Health Care AlphaDEX Fund (FXH) and ROBO Global Robotics & Automation ETF (ROBO).

Globus Medical issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $2.30-$2.30 for the period, compared to the consensus EPS estimate of $2.30. The company issued revenue guidance of $1.10 billion-$1.10 billion, compared to the consensus revenue estimate of $1.10 billion.

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Globus Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.49%), Wellington Management Group LLP (2.73%), State Street Corp (2.28%), William Blair Investment Management LLC (1.86%), Nuance Investments LLC (1.84%) and JPMorgan Chase & Co. (1.83%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends.

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GMED stock can currently be purchased for approximately $52.51.

Globus Medical (NYSE:GMED) has a market capitalization of $5.27 billion and generates $759.12 million in revenue each year. The medical device company earns $190.17 million in net income (profit) each year or $1.97 on an earnings per share basis.

The company employs 2,600 workers across the globe.

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042.